Key facts
- It has raised $18.7M; the latest was Accelerator/Incubator in Dec 2024.
- Notable investors include Tech Incubator Program for Startup, DAYLI Partners, Kolon Investment, NH Investment & Securities, Huons Global — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for G2e
- ·The full record, as it builds
Funding rounds
No funding rounds for G2e are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About G2e
Developer of an IoT-based insulin device designed for blood sugar management. The company's product is based on a combination of platform-based medical IoT and a cloud-based application that can quickly and easily display, analyze, and store blood sugar information and provides mobile hospital services in case of emergency, enabling patients to track and manage their insulin levels at convenience.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 1999
- Employees
- 73
- Website
- g2e.co.kr/
- Ownership
- Privately Held (backing)
G2e doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in G2e shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on G2e in its N-PORT filings yet. We sweep new filings monthly.